Anixa Biosciences to develop AI-guided cancer vaccines with Verdi Solutions

Anixa Biosciences (ANIX) has entered into a letter of intent with Verdi Solutions to develop personalized and off-the-shelf peptide vaccines for cancer patients. Verdi Solutions, headquartered in Vienna, Austria, is pioneering personalized cancer treatment by integrating artificial intelligence and advanced cloud computing to accelerate the development and implementation of personalized cancer vaccines. Additionally, the company is developing off-the-shelf cancer vaccines, paired with companion diagnostics to identify likely responders and optimize treatment outcomes. Verdi has developed personalized vaccines using sequence data from the primary tumors for three patients with bone metastases. Verdi has granted Anixa a six-month exclusive right to negotiate a transaction for the research, development, and commercialization of Verdi’s cancer vaccines. While Verdi continues to develop personalized vaccines for individual treatment attempts in Europe, Verdi and Anixa plan to initiate clinical trials in the U.S.